title: IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors.
abstract: IL-8 is a potent proinflammatory cytokine that has a key role in the recruitment and activation of neutrophils during inflammation. IL-8 reacts with neutrophils via two distinct types of IL-8-R. Receptor-specific Abs were raised against peptides derived from the first extracellular domain of each IL-8-R. Anti-IL-8-R1 and anti-IL-8-R2 selectively block 125I-IL-8 binding to rIL-8-R type 1 or 2, respectively. The anti-peptide Abs were used to assess the role of each receptor in the chemotactic response of neutrophils to GRO alpha and to IL-8. Anti-IL-8-R2 blocks GRO alpha-induced chemotaxis of neutrophils. Chemotaxis to GRO alpha is not inhibited by anti-IL-8-R1. Thus GRO alpha stimulates chemotaxis exclusively through IL-8-R2 and independently of IL-8-R1. Surprisingly, anti-IL-8-R1 inhibits the majority (78 +/- 3%) of IL-8-induced neutrophil chemotaxis. Only a minor proportion of IL-8-induced chemotaxis (29 +/- 5%) is inhibited by anti-IL-8-R2. These findings indicate that chemotaxis to IL-8 is mediated predominantly by type 1 IL-8-Rs and suggest that IL-8-R1 is an appropriate target for therapeutic strategies to limit neutrophil influx in diseases where neutrophils contribute to pathophysiology.
authors.affiliation: Chiron Corporation, Emeryville, CA 94608, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Hammond
authors.forename: G R
authors.initials: GR
authors.lastname: Lapointe
authors.forename: P H
authors.initials: PH
authors.lastname: Feucht
authors.forename: S
authors.initials: S
authors.lastname: Hilt
authors.forename: C A
authors.initials: CA
authors.lastname: Gallegos
authors.forename: C A
authors.initials: CA
authors.lastname: Gordon
authors.forename: M A
authors.initials: MA
authors.lastname: Giedlin
authors.forename: G
authors.initials: G
authors.lastname: Mullenbach
authors.forename: P
authors.initials: P
authors.lastname: Tekamp-Olson
mesh_terms: D000595:Amino Acid Sequence; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D000918:Antibody Specificity; D002630:Chemotactic Factors / Q000494:pharmacology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D006133:Growth Substances / Q000494:pharmacology; D016209:Interleukin-8 / Q000494:pharmacology*; D008969:Molecular Sequence Data; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D018123:Receptors, Interleukin / Q000187:drug effects* / Q000502:physiology; D023062:Receptors, Interleukin-8A; D011993:Recombinant Fusion Proteins / Q000378:metabolism / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000906:Antibodies; D002630:Chemotactic Factors; D006133:Growth Substances; D016209:Interleukin-8; D018123:Receptors, Interleukin; D023062:Receptors, Interleukin-8A; D011993:Recombinant Fusion Proteins; D009240:N-Formylmethionine Leucyl-Phenylalanine